As we take stock this World Hepatitis day, a mere 11 years from the World Health Organization’s (WHO) 2030 target date for global Hepatitis C Virus (HCV) elimination (a 90% reduction in new diagnoses and 65% reduction in mortality [1]), there is still a very long way to go.

Only nine high-income countries (Australia, France, Iceland, Italy, Japan, South Korea, Spain, Switzerland and the United Kingdom) are on track to eliminate HCV by 2030 (Figure 1) [2]. In fact, 80% of high-income countries are not on track to meet the WHO targets, and it is estimated that at the current pace of implementation, 67% will not reach elimination targets before 2050, if ever. Although “on-track” countries include some of those with high burdens of infection such as Italy and Japan, they represent only an estimated 8.5% of the world’s 71 million people living with HCV [3]. Notably, except Georgia, no country in Eastern Europe or central Asia where HCV infection rates continue to rise unabated among people who inject drugs, is on track.

In low- and middle-income countries (LMICs), there are also some exceptional leaders such as Egypt and Pakistan. However, in far too many countries, the scope of the problem is not even known, let alone efforts at elimination begun [4].

Yes, the elimination goals are ambitious. But let’s be clear. We have the tools at our disposal to eliminate HCV as a public health threat – safe, simple curative treatment, accurate diagnostics and knowledge about how transmission can be prevented. The question is, can we mobilize these tools rapidly enough and implement them widely and equitably?

Slow scale-up will only serve to perpetuate the epidemic over decades and the major health gains associated with HCV treatment will be thwarted. Moreover, the momentum that has built in response to the WHO call to action will be squandered as other important health, social and environmental needs inevitably eclipse this cause.

Only rapid action will yield measurable impact in the short term – modelling predicts greater benefit in prevention of new infections and reductions in decompensated cirrhosis and liver-related deaths will be realized with rapid scale-up of prevention, treatment and screening measures [5-7]. Indeed, real world evidence is beginning to confirm this modelling with tangible gains in life expectancy, reduced hospitalizations, liver transplantation and lower rates of new infections [8,9]. As a result, significant savings in health costs are projected. This is a message that policy makers need to hear.

So, what can we learn from the countries that are well along the road to success? These countries uniformly have in common two things: engagement at the highest political level and well designed and executed national action plans.

It is not necessary, however, to wait for a top down approach. Even in the absence of high-level political commitment, country specific strategies can be developed. An excellent example of this is Canada’s recently published “Blueprint to Inform Hepatitis C Elimination Efforts in Canada” [7]. It was developed through a consultative and inclusive process involving researchers, clinicians, policy makers, community-based organizations and people with lived experience. The Blueprint lays out specific targets, some more ambitious than those of the WHO. Most importantly, it is focused on the needs of priority populations — those who experience a disproportionate burden of HCV or who have challenges accessing HCV care and services. It offers options that can be tailored to different contexts and cultures, and is truly a model of how to advance the elimination agenda when government leadership is lacking and jurisdictional and social barriers are entrenched. But action plans are only the beginning.

Digging deeper, a key feature of successful elimination programmes has been disruption in the normal way of doing business. Disruptive innovation, a business concept coined by Clayton Christensen in 1995, refers to a product that takes root initially at the bottom of a market and then relentlessly moves up, eventually displacing established competitors [10]. Generic direct-acting antivirals (DAAs), by forcing down all DAA prices, have been truly disruptive serving to catalyse elimination programmes worldwide. Indeed, the impact of generic DAAs has had much broader effects by rapidly driving down the cost of diagnostic tests. These changing market forces may ultimately have a lasting impact on all patented medications and diagnostics making health care more equitable.

Rapidly falling drug prices are the result of many forces and actors and are the essential third pillar to successful...
Voluntary and compulsory licenses, patent opposition, joint procurement and personal importation schemes have been some of the effective strategies. A 12-week generic pan-genotypic treatment is now as low as $84 in Egypt, $60 in Rwanda and $39 in India – much lower than the floor price of $200 initially predicted [11]. Diagnostic tests costs have likewise fallen from $100 to $1 for a rapid antibody test and $10 for HCV RNA testing. Compare this to treatment costs of over $40,000 in the US [12]. Prices also can come down in high-income settings. Australia successfully negotiated a volume-based, risk-sharing deal with pharmaceutical companies that have allowed them to treat over 80,000 people with HCV for an estimated $8000 per treatment course [13]. Italy and Spain have similarly procured DAAs at €8000 per course [13].

But perhaps most disruptive has been the progress made in LMICs in HCV treatment programmes more broadly. Indeed, the successful backward transfer of elimination approaches from LMICs to high-income settings would be a truly revolutionary impact of DAAs. A good illustration is the Clinton Health Access Initiative Quick Start model [4]. This programme, launched in 2016 in Ethiopia, Indonesia, Myanmar, Nigeria, Rwanda and Vietnam with very modest investment, focuses on programme simplification and market shaping to reduce commodity pricing. It includes fast track registration of quality-assured products, pricing negotiations for both diagnostics and drugs, simplification of national diagnostic and treatment algorithms, decentralized public health approaches to care delivery and leveraging existing HIV care infrastructure.
So political action can be leveraged, costs can be contained and service delivery can change, rapidly, and in a variety of very challenging settings. However, elimination efforts have been very slow in most high-income settings despite their greater resources. Fragmented health systems and multiple payers result in the inability to innovate rapidly. Lack of transparency in drug pricing and a strong pharmaceutical lobby has kept drug costs high. Siloed health budgets and the reluctance to relinquish antiquated models of specialist based care delivery additionally contribute to a state of inertia in health systems [14].

Governments have bulk buying power, and in the face of major public health crises, can leverage it to negotiate lower prices if they so choose [15]. High-income countries need to capitalize on this to a lower drug and diagnostic costs for diseases with major public health impact – not just for HCV. It is a matter of the very sustainability of healthcare.

Despite progress on many fronts, there are remaining challenges in need of disruptive solutions, even in on track countries. Screening, case finding and linkage to care in populations that have been disenfranchised from health systems remains difficult and has emerged as the major roadblock to finalizing elimination. As more and more people are cured, cases will be harder and harder to find. Re-infections will need to be detected and treated early to avoid new outbreaks. This will be particularly important so as not to backslide on the major progress towards elimination that has been made among certain key populations, such as men who have sex with men in Europe [16,17]. Diagnostic testing algorithms will therefore need to change. We will have to move to primary screening with antigen or RNA-based testing rather than antibody testing. Only then will rapid, point-of-care technologies aimed at diagnosing active infections become attractive to developers and costs come down.

Stigma persists and is a barrier for people to seek prevention and treatment services. In an ideal world, curative therapy should normalize HCV infection. Unfortunately, restrictive and punitive drug policies serve to marginalize those bearing the greatest burden of infection. There are many parallel harm reduction innovations emerging such as supervised injection sites [18], prescription heroin [19], and even needle and opioid dispensing machines [20] that if scaled up and paired with elimination efforts could reduce overdoses and help disrupt HCV transmission. Decentralized, destigmatized community-based models of service delivery tailored to the needs of specific populations are also urgently required.

Several countries have shown us that HCV elimination is possible in both high-income and low-income settings. We need to follow and build on their lead. If we succeed in this endeavour, we will not only reduce suffering, save millions of lives and billions in health costs, the resulting disruptive innovations will fundamentally change the way healthcare is delivered to all.

**AUTHORS’ AFFILIATIONS**

Department of Medicine, McGill University Health Centre, Montreal, Canada

**COMPETING INTERESTS**

MBK received research grants for investigator-initiated trials from Merck, Gilead and ViV HealthCare; consulting fees from Merck, Gilead and AbbVie. MBK is also supported by a Tier 1 Canada Research Chair.

**AUTHORS’ CONTRIBUTIONS**

MBK was the sole contributor to the preparation of the manuscript.

**REFERENCES**

1. World Health Organization. Global hepatitis report. Geneva, Switzerland: World Health Organization. 2017 [cited 2019 Jan 30]. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report-2017/en/

2. Razavi H. Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets. Poster SAT-260. The International Liver Congress 2019: 15-19 April 2019; Vienna, Austria.

3. European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC. 2016 [cited 2019 July 1]. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/systematic-review-hepatitis-B-C-prevalence.pdf

4. World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. Geneva, Switzerland: World Health Organization. 2018. (WHO/CDS/HIV/18.4). [cited 2019 Jul 01]. Available from: https://www.who.int/hepatitis/publications/hep-access-report-2018/en/

5. Heffernan A, Cooke GS, Nayagam S, Thurnz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319–29.

6. Kwon JA, Dore GJ, Grebely J, Hajarizadeh B, Guy R, Cunningham EB, et al. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study. J Viral Hepat. 2019;26(1):83–92.

7. The Canadian Network on Hepatitis C. Blueprint Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination efforts in Canada. Montreal, QC. 2019 [cited 2019 Jul 01]. Available from: http://www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf

8. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–64.

9. Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71(2):281–8.

10. Christensen C. Disruptive innovation. 2019 [cited 2019 Jul 21]. Available from: http://claytonchristensen.com/key-concepts/

11. Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Erad. 2016;2(1):28–31.

12. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer. 2016;11:24.

13. Douglass CH, Pedrana A, Lazarus JV, ‘t Hoen EFM, Hammad R, Leite RB, et al. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med. 2018;16(1):175.

14. Collier R. Canadian health care lacks culture of innovation. CMAJ. 2018;190(36):E1089–90.

15. Brennan H, Kapczynski A, Monahan CH, Rizvi Z. A prescription for excessive drug pricing: leveraging government patent use for treat hepatitis C. J Virus Erad. 2016;2(1):28–31.

16. Hoornenborg E, Achterberg RCA, Schim van der Loef MF, Davidovich U, Hogewoning A, de Vries HJC, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS. 2017;31(11):1603–10.

17. Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, Hogewoning A, de Vries HJC, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS. 2017;31(11):1603–10.

18. Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, et al. Declining Hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71(2):281–8.

19. Collier R. Canadian health care lacks culture of innovation. CMAJ. 2018;190(36):E1089–90.

20. Brennan H, Kapczynski A, Monahan CH, Rizvi Z. A prescription for excessive drug pricing: leveraging government patent use for treat hepatitis C. J Virus Erad. 2016;2(1):28–31.